PHAT - Phathom Pharmaceuticals, Inc.
IEX Last Trade
7.5
-11.730 -156.400%
Share volume: 0
Last Updated: Tue 24 Dec 2024 06:18:17 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
19.80%
PREVIOUS CLOSE
CHG
CHG%
$19.23
-11.73
-61.00%
Fundamental analysis
28%
Profitability
26%
Dept financing
25%
Liquidity
50%
Performance
25%
Performance
5 Days
0.67%
1 Month
-17.49%
3 Months
-57.51%
6 Months
-27.40%
1 Year
-16.76%
2 Year
-33.57%
Key data
Stock price
$7.50
DAY RANGE
$7.72 - $19.23
52 WEEK RANGE
$6.39 - $19.71
52 WEEK CHANGE
-$19.01
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Terrie Curran
Region: US
Website: phathompharma.com
Employees: 110
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: phathompharma.com
Employees: 110
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Phathom Pharmaceuticals, Inc. focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.
Recent news